Several preclinical and clinical studies have indicated that SGLT2 inhibitors (canagliflozin, dapagliflozin, and empagliflozin) show anti-cancer activity in many types of cancers, including hepatocellular carcinoma (HCC) [33,188,189,190], pancreatic cancer [191], squamous cell carcinoma [192], renal cell carcinoma [193], prostate cancer [34], cervical cancer [194], lung cancer [30,34], breast cancer [195] and colon cancer [196]. Here, SLC5A2 is linked to hepatocellular carcinoma.